Overview

Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
Female
Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. Chemotherapy uses different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with hormone therapy may kill more tumor cells. It is not yet known which treatment regimen is most effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of tamoxifen with that of ovarian ablation, and/or combination chemotherapy in treating premenopausal women with stage I, stage II, or stage IIIA breast cancer.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Scottish Cancer Therapy Network
Treatments:
Cyclophosphamide
Fluorouracil
Goserelin
Leuprolide
Methotrexate
Tamoxifen
Criteria
DISEASE CHARACTERISTICS: Histologically proven unilateral, invasive breast cancer Stage
T0-3, N0-1, M0 No carcinoma in situ alone, including Paget's disease of the nipple without
underlying invasion No evidence of distant disease, including ipsilateral supraclavicular
node enlargement unless proven benign No history of pure carcinoma in situ in either breast
Hormone receptor status: Not specified

PATIENT CHARACTERISTICS: Age: 70 and under Sex: Female Menopausal status: Premenopausal,
defined by 1 of the following criteria: Last menstrual period less than 1 year before
surgery Under age 50 with prior hysterectomy (for nonmalignant reason) without bilateral
oophorectomy Under age 50 and on continuous oral contraception If at variance with the
above definitions, hormonal assays in the premenopausal range take precedence Performance
status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic:
Not specified Renal: Not specified Other: Not pregnant or nursing No other serious illness
No other prior invasive malignancy except adequately treated basal cell or squamous cell
skin cancer

PRIOR CONCURRENT THERAPY: Not specified